AGM Statement

RNS Number:3375D
BBI Holdings PLC
05 September 2007

For release

05 September 2007



                                BBI HOLDINGS PLC

                                 AGM STATEMENT


BBI Holdings Plc ('BBI'), the AIM listed developer and manufacturer of rapid
result diagnostic tests and reagents for the diagnostic industry, held its
Annual General Meeting today at its offices in Cardiff at 11am. All resolutions
were duly passed.

Following the formal proceedings of the AGM, David Evans, Chairman of BBI, made
the following statement:

"In July I was pleased to be able to report that 2007 had been another
successful year for BBI, during which turnover increased 53.2% to #9.73m and pre
tax profit rose 86% to #1.83m. This was achieved through continued organic
growth combined with our strategic acquisitions.



Regarding current trading:



"I am pleased to announce that turnover for the five month period to 31 August
2007 has grown significantly and this is in line with management expectations.
Turnover for the period is up 107% on last year. This increase is largely due to
the acquisition of Theratase in May 2007, but has also come from a 13.2%
increase in like for like sales.   The acquisition of Theratase has made BBI one
of the world's leading reagent and test suppliers.

"The actions and initiatives your Board has put in place are expected to result
in further improvements in organic growth in the second half of the year, and
the Board of BBI looks forward to continued progress through the remainder of
the current financial year."



ENDS





For further information please contact:


BBI Holdings plc                                      Parkgreen Communications Ltd
Julian Baines, Managing Director                      Ben Knowles
Tel: [phone]                                    Tel: [phone]
                                                      Mob. [phone]
www.bbigold.com                                       Email: [e-mail]



Background notes:

About BBI Holdings PLC (AIM: BBI):


BBI is a leading supplier of products and services to the global diagnostic and
healthcare industries. BBI floated on AIM on 28 April 2004 at 47p.


BBI operates in three core areas:

1. BBInternational (diagnostics)

Incorporating:

         British Biocell, Cardiff, UK
         BBI Dundee (formerly Alchemy Laboratories), Dundee, UK
         BBI Research, Madison, Wisconsin, USA
         Qnostics, Glasgow, UK

BBI manufactures superior quality gold reagents which are used to bind with
specific antibodies or antigens, which are used in diagnostic tests to provide a
positive or negative visual signal. BBI also provides contract product
development services for leading diagnostic companies using its expertise to
develop rapid result diagnostic tests. BBI also manufactures rapid result
diagnostic tests in the UK and the US. Rapid test manufacture involves placing
conjugate onto a pad or strip and enclosing this within a preformed plastic
package 'housing' designed to the customer's specifications.  BBI's Qnostics
division supplies molecular quality control reagents to the global market place.



www.bbigold.com



2. BBI Enzymes



Incorporating:

         Biozyme, Blaenavon, UK
         Seravac, Cape Town, S Africa.


Theratase was acquired by BBI in May 2007 to form BBI's enzyme division. Biozyme
and Seravac are leading manufacturers and suppliers of high quality specialist
natural enzymes to the medical diagnostics industry. Enzymes are proteins which
drive complex reactions that occur in all living organisms. Their high
specificity and dramatic catalytic activity has been exploited within the
diagnostic industry.



www.biozyme.com

www.seravac.com



3. BBI Healthcare (diabetes)



Brands:

         GlucoGel
         SensoCard Plus
         GlucoTabs


In April 2004 BBI acquired Hypostop (now renamed GlucoGel in the UK). GlucoGel
is an easy to use dextrose gel which is included in the National Institute for
Clinical Excellence's (NICE) treatment guideline for hypoglycaemia. BBI
Healthcare was founded in April 2006 to manage the sales and marketing of
GlucoGel, and build a diabetes care product portfolio. In July 2006 BBI acquired
the UK's only talking blood glucose meter for the visually impaired called
SensoCard Plus. The acquisition gives BBI exclusive distribution rights for
within the UK, US, Canada and India.




www.bbihealthcare.com




                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

AGMEAFNSEAPXEFE